Phase III failure signals
Phase III stopped trials carry the strongest biological-signal share
497 of 3,975 stopped Phase III records (12.5%) carry efficacy/futility or safety signals, the highest share among the major development phases.
- The current database contains 3,975 stopped records that include a Phase III label.
- 497 Phase III records, or 12.5%, are classified as likely biological failure signals.
- Efficacy/futility accounts for 354 Phase III records, compared with 143 safety records.
- Operational reasons account for 1,816 stopped Phase III records, while 1,640 are other or unknown.
- The denominator contains stopped Phase III records only, so this is not an overall Phase III failure rate.
The headline result
Phase III is where clinical development becomes expensive, confirmatory, and much more visible. In the current stopped-trial database, 497 of 3,975 Phase III records (12.5%) are classified as likely biological failure signals. That is the highest share among the major development phases represented here.
The result is directionally useful, but it needs careful wording. It does not mean that Phase III trials have that overall failure rate. The denominator contains stopped trials only. It tells us how stop reasons are distributed inside the stopped Phase III slice.
Why Phase III stop reasons matter
A Phase III program usually tests a more mature clinical hypothesis in a larger population, often against a comparator and with endpoints intended to support regulatory decisions. When such a trial stops for futility, insufficient efficacy, a missed endpoint, or safety, the signal can carry more development weight than a vague administrative stop.
That still does not make every Phase III termination a failed drug. Sponsor strategy, recruitment, funding, feasibility, changes in standard of care, and incomplete registry explanations remain part of the dataset. Status and reason must be separated before interpreting the program.
Efficacy is the larger scientific signal
Within stopped Phase III records, efficacy and futility signals appear more often than safety signals. That makes sense for a phase designed to test whether an intervention provides enough benefit in a defined population and endpoint framework.
The difference matters analytically. A futility or missed-efficacy signal raises questions about treatment effect, endpoint assumptions, comparator performance, or patient selection. A safety stop raises a different set of questions around toxicity, exposure, benefit-risk, and monitoring decisions.
Operational and unclear stops still dominate
Even in Phase III, likely biological signals are not the majority of stopped records. Operational and other/unknown reasons together account for most of the slice. That prevents a simple conversion from stopped status to failed intervention.
The other/unknown category is especially important. Registry explanations can be generic, short, or absent. A conservative database should preserve that uncertainty rather than manufacture a scientific explanation the source does not support.
How I would review a stopped Phase III trial
I would begin with the exact why-stopped language and then verify the registered primary endpoint, statistical design, interim-analysis plan, enrollment, and comparator. Next I would look for sponsor disclosures, publications, regulatory documents, and any timing mismatch between the public announcement and registry update.
For comparative work, I would keep disease area and modality constant. Comparing an oncology combination trial with an infectious-disease vaccine or cardiovascular outcomes study can hide more than it reveals. Phase alone is useful, but it is not enough context.
What this analysis cannot tell us
This dataset does not contain the full denominator of all Phase III trials that succeeded, completed normally, or remain ongoing. It therefore cannot estimate the probability that a Phase III trial will fail or establish the probability of technical and regulatory success.
The result is best treated as a composition analysis of stopped records. It helps identify where source language points toward efficacy or safety and where the available explanation remains operational or unclear.
Stopped Phase III reason mix
| Reason classification | Phase III records |
|---|---|
| Operational | 1,816 |
| Other/unknown | 1,640 |
| Efficacy/futility | 354 |
| Safety | 143 |
| Regulatory | 22 |
Biological-signal share across major phases
| Development phase | Signals / stopped records |
|---|---|
| Phase III | 12.5% (497 / 3,975) |
| Phase II | 9.1% (973 / 10,743) |
| Phase I | 6.5% (428 / 6,629) |
| Phase IV | 3.0% (85 / 2,871) |
Continue from here
FAQ
Do Phase III trials have the highest clinical failure rate?
This analysis cannot answer that question because it contains stopped trials only. It shows that Phase III has the highest biological-signal share within the stopped records of the major phases.
Are most stopped Phase III trials biological failures?
No. Operational and other or unknown stop reasons still make up most stopped Phase III records in the database.
Which biological signal is more common in stopped Phase III trials?
Efficacy and futility signals are more common than safety signals in the current stopped Phase III slice.
Source note: counts are generated from the current ClinicalTrials.gov-derived stopped-trial dataset used by ClinicalTrialFailures.com. These labels are analytical screening signals, not medical advice.